根据美国证券交易委员会最新文件披露，生物制药公司MeiraGTx Holdings Plc与强生旗下杨森公司达成的XLPR合作协议中，包含一项价值5000万美元的或有付款条款。
该笔款项的支付将完全取决于RPGR基因治疗产品能否实现预设的研发里程碑。协议细节显示，这笔或有资金将在特定临床开发节点触发支付机制，体现出合作方对创新疗法商业价值的共同期待。
此次披露的财务安排进一步印证了双方在眼科基因治疗领域的深度绑定。里程碑付款作为生物科技领域常见的合作模式，既降低了药企前期投入风险，又为研发企业提供了明确的价值实现路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.